Last updated on March 2019

Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

Brief description of study

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

Clinical Study Identifier: NCT02924402

Find a site near you

Start Over

Centre Henri Becquerel

Rouen, France
  Connect »